Novo Nordisk Stock Plunges 18% After Ozempic Sales Warning
In a sharp market reaction, Novo Nordisk's stock plunged 18 percent following a sales warning for its blockbuster GLP-1 medications, Ozempic and Wegovy, in the key US market. The Danish pharmaceuticals giant, one of Europe's largest by market capitalization, saw its shares drop to around 302 kronor ($34) in afternoon trading on the Copenhagen stock exchange. This decline wiped nearly $32 billion off the company's market value since Tuesday, underscoring the volatility tied to GLP-1 drug sales forecasts.
The announcement came as Novo Nordisk reported that 2025 sales had risen six percent to 309 billion kronor ($48.9 billion), falling short of the eight to 11 percent gain forecasted just months earlier in November. Looking ahead, the company now expects sales to slide by up to 13 percent this year as prices for Ozempic and Wegovy fall in the United States. This guidance for sales and operating profit to fall 5-13 percent triggered the immediate sell-off, erasing much of the shares' gains accumulated earlier in the year.
Market Context for GLP-1 Leaders
Ozempic (semaglutide injection for type 2 diabetes) and Wegovy (higher-dose semaglutide for chronic weight management) have dominated the GLP-1 receptor agonist market. These drugs mimic the GLP-1 hormone to regulate blood sugar, slow gastric emptying, and reduce appetite, leading to significant weight loss and cardiovascular (CV) benefits. However, intense competition from rivals like Eli Lilly's Mounjaro (tirzepatide) and looming patent pressures have contributed to pricing dynamics in the US.
CEO Mike Doustdar's Perspective on Price Reductions
Chief executive Mike Doustdar framed the price cuts strategically during the results presentation:
"Price reduction in some ways is our investment for the future and for capturing more patients,"
he said. This approach aims to broaden access to GLP-1 therapies amid rising demand for metabolic health treatments. For patients with obesity or type 2 diabetes, lower prices could mean greater affordability, potentially expanding the patient pool despite short-term revenue hits.
Analyst Insights on External Pressures
Derren Nathan, an analyst at Hargreaves Lansdown, attributed the downturn to multiple factors:
"Donald Trump's crusade on drug prices, patent expiration, and competition all had their part to play."
Nathan noted the new underlying guidance as a welcome but sobering initiative from the company. US drug pricing reforms,
compounded by generic threats post-patent and rivals gaining market share, have intensified scrutiny on Novo Nordisk's profitability.
Positive Outlook: FDA Approval of Wegovy Pill
Amid the gloom, Novo Nordisk highlighted a major milestone. In December, the US Food and Drug Administration (FDA) approved a pill form of Wegovy for weight loss, moving away from injections. The company now expects similar approval in Europe in the second half of this year.
CEO Doustdar emphasized its potential:
"The Wegovy pill gives you 16.6 percent weight loss in addition to all the CV [cardiovascular] benefits." "This is not just a pill, it's a peptide, it's a large protein inside the pill that gives you that incredible efficacy,"
he added. This oral semaglutide formulation uses advanced peptide technology to deliver the active ingredient without needles, addressing a common barrier for patients.
How the Wegovy Pill Works: A Deeper Look
GLP-1 agonists like semaglutide activate receptors in the pancreas, brain, and gut. The oral version protects the peptide from stomach acid degradation, enabling effective absorption. Clinical trials showed the 16.6 percent average weight loss, alongside reductions in major adverse cardiovascular events (MACE), such as heart attacks and strokes—benefits established in large-scale studies like SELECT for Wegovy.
For patients, this means a convenient alternative to weekly injections. Those considering the switch should discuss with their healthcare provider, monitoring for common GLP-1 side effects like nausea, vomiting, or gastrointestinal issues, which may differ slightly in oral form.
Broader Implications for GLP-1 Therapy and Patient Access
The US price erosion reflects a maturing GLP-1 market, where demand for obesity and diabetes treatments outpaces supply. Lower prices could accelerate adoption, benefiting the 42% of US adults with obesity. However, short-term sales dips pressure innovators like Novo Nordisk to invest in next-gen peptides.
Comparing Ozempic and Wegovy to Alternatives
Ozempic (2.4 mg max weekly dose for diabetes) and Wegovy (up to 2.4 mg for weight loss) lead, but dual agonists like tirzepatide offer potentially higher efficacy (up to 20%+ weight loss in trials). Still, Novo Nordisk's portfolio dominance and the oral innovation position it strongly long-term.
Safety Considerations with GLP-1 Medications
While effective, GLP-1 drugs carry risks including pancreatitis, gallbladder issues, and thyroid tumors in rodents (human risk unclear). The FDA label warns of these, emphasizing medical supervision. Patients on Ozempic or Wegovy should report persistent symptoms; apps like Shotlee can help track side effects, dosages, and symptom patterns for better doctor discussions.
Practical Guidance for Patients and Providers
- Who benefits most? Adults with BMI ≥30 or ≥27 with comorbidities like hypertension.
- What to discuss: Price access via coupons, prior authorizations, or compounded alternatives; transition to oral if needle-averse.
- Monitoring: Weight, blood sugar, CV risk factors quarterly.
Key Takeaways
- Novo Nordisk's stock fell 18% after projecting up to 13% sales drop for Ozempic/Wegovy due to US price cuts.
- 2025 sales grew 6% to 309 billion kronor, below expectations.
- CEO views price reductions as growth investment; Wegovy pill promises 16.6% weight loss + CV benefits.
- FDA approved oral Wegovy; Europe expected H2 this year.
- Competition, pricing pressures, and patents drive challenges, but peptide innovations fuel optimism.
Conclusion: Navigating GLP-1 Market Volatility
Novo Nordisk's sales warning highlights the high stakes in GLP-1 dominance, but the Wegovy pill signals innovation ahead. For investors, it's a dip-buy opportunity; for patients, expanding access to proven metabolic therapies. Stay informed on approvals and pricing—consult providers for personalized peptide therapy plans. This blend of financial turbulence and clinical promise defines the evolving landscape of Ozempic and Wegovy.
